MedTrace Logo

Ridge Augmentation Treatment Using OSSIX® BREEZE vs Jason®

NCT05584566 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 65

Last updated 2024-10-16

No results posted yet for this study

Summary

This is a prospective randomized controlled parallel trial. The aim of this study is to evaluate bone formation and soft tissue healing after 4 and 8 months in patients with ridge deficiencies in simultaneous implantation approach. The trial will compare a (sugar cross linked) - SCL pericardium membrane OSSIX® Breeze vs native pericardium membrane (Jason®).

Conditions

  • Ridge Augmentation

Interventions

DEVICE

OSSIX Breeze

barrier membrane

DEVICE

Jason membrane

barrier membrane

Sponsors & Collaborators

  • Datum Dental LTD

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-12-01
Primary Completion
2026-06-01
Completion
2026-07-01

Countries

  • Israel
  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05584566 on ClinicalTrials.gov